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Adjuvancy and reactogenicity of 
N-acetylglucosaminyl-N-acetylmuramyl- 
dipeptide (GMDP) orally administered 
just prior to trivalent influenza subunit 
vaccine. A double-blind placebo- 
controlled study in nursing home 
residents 
A.M. Palache*, W.E.P. Beyer *, E. Hendriksent, L. Gerezj-, R. AstonS, 
P.W. Ledge& V. de Regtg, R. Kerstensg, Ph.H. Rothbarth* and 
A.D.M.E. Osterhaus*q 
One hundred and fifty-three nursing home residents received 0, 5, 2.5 or 50 mg 
N-acetylglucosaminyl-N-acetylmuramyl-dip (GMDP) orally, and trivalent intu- 
enza subunit vaccine intramuscularly. One day after intervention, there was a strong 
increase of total leucocytes, monocytes and neutrophils in the groups receiving 2.5 or 50 mg 
GMDP. A GMDP dose dependent increase in systemic, but not in local, vaccine 
side-effects was observed. No signtficant dtyerences in post-vaccination haemagglutination 
inhibiting serum antibody titres were observed between the four groups, indicating that 
oral administration of GMDP together with influenza vaccination, does not lead to a 
higher vaccine eficacy. Copyright 0 1996 Elsevier Science Ltd. 
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N - acetylglucosaminyl - N - acetylmuramyl - dipeptide 
(GMDP), an analogue of muramyl-dipeptide, has 
adjuvant properties and low toxicity in animal models 
and human beings’. These characteristics uggested its 
use as a vaccine-adjuvant in the elderly, a prominent 
target group for influenza immunization, as the elderly 
generally show a less favourable antibody response to 
influenza vaccine than young adults2. 
SUBJECTS, MATERIALS AND METHODS 
Intake procedure 
In the Fall of 1994, the 275 residents of a Dutch 
nursing home were invited to participate in the study. 
*WHO National Influenza Centre, and Foundation for 
Respiratory Virology, particularly, Influenza, Institute of 
Virology, Erasmus University Rotterdam, P. 0. Box 1738, 
3000 DR, Rotterdam, The Netherlands. TNursing Home 
Den Ooiman, Doetinchem, The Netherlands. SPeptech 
(UK) Ltd, Cirencester, UK. &Solvay-Duphar BV, Weesp, 
The Netherlands. To whom correspondence should 
be addressed. (Received 22 December 1995; revised 
15 January 1996; accepted 3 March 1996) 
Exclusion criteria were: allergy to chicken protein; 
terminal stage disease; kidney diseases or failure; and 
medication that may influence the immune system. 
Candidates, or in case of dementia their relatives, signed 
an informed consent prior to the study. Approval for the 
study was obtained from the Ethics Committees of the 
Erasmus University Rotterdam and the nursing home. 
Vaccine and adjuvant 
Commercial trivalent subunit influenza vaccine 
(Influva@, Solvay-Duphar BV, Weesp, The 
Netherlands) contained 15 lug haemagglutinin of the 
influenza viruses AlShangdongl9193 (H3N2), A/Taiwan/ 
l/86 (HlNl) and B/Panama/45/90, respectively, accord- 
ing to the recommendations of the World Health 
Organization for the winter season 1994/19953. GMDP 
manufactured and formulated into tablets under good 
manufacturing practice conditions, were supplied by 
Peptech (UK) Ltd, Cirencester, UK. 
Administration of vaccine and GMDP, and recording of 
the side-effects 
One hundred and fifty-three participants received 0, 
5, 25 or 50 mg GMDP orally, according to a 
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Table 1 Demographic parameters 
GMDP 
(mg) 
Number of subjects 
entering the study 
Number of 
deaths 
Subjects completing the study 
Number Age (years)” Gender* PVC 
0 43 1 42 78.4 (75.0-81.7) 10 (23.8) 32 (76.2) 
5 44 1 43 83.0 (80.0-86.0) 9 (20.9) 32 (74.4) 
25 42 2 40 81.3 (78.7-83.9) 13 (32.5) 30 (75.0) 
E 24 153 5 1 23 148 77.3 80 (77.3-81.6) 
(78.7-81.9) 
6 38 (26.1) 
(25.7) 
23 117 (100.0) 
(79.1) 
aArithmetic mean (95% Cls); *number (%) of male subjects; ‘number (%) of subjects vaccinated within 5 years prior to study 
Table 2 Frequency of side-effects 
Logistic regression 
Total (%) 
Doses GMDP (%) (P-value)” 
Symptom (rk148) 0 mg (1x42) 5 mg (n=43) 25 mg (n=40) 50 mg (n=23) GMDP Gender Disease 
Any local reaction 55 (37.2) 17 (40.5) 19 (44.2) 13 (32.5) 6 (26.1) N.S.* 0.0030 N.S. 
Any systemic reaction 44 (29.7) 7 (16.7) 7 (16.3) 20 (50.0) 10 (43.5) 0.0003 N.S. 0.0001 
Moderate and severe inconvenience 30 (20.3) 3 (7.1) 6 (14.0) 16 (40.0) 5 (21.7) 0.0038 N.S. 0.0001 
aLogiStiC regression with gender (male, 1; female, 0), dose GMDP (0 mg, 1; 5 mg, 2; 25 mg, 3; 50 mg, 4) and underlying disease group 
(psychogeriatric, 1; somatic, 2) as independent variables. f-value of regression coefficient. *N.S., not significant (0.05) 
randomization scheme, and under double-blind con- 
ditions. The vaccine was injected intramuscularly in the 
deltoid muscle directly after GMDP/placebo intake. 
During the first 3 days after intervention, subjects were 
seen by a trained study collaborator to record reactions, 
using a standardized questionnaire. The questionnaire 
addressed nine local symptoms (redness, swelling, 
itching, warmth, pain on contact, continuous pain, 
restriction of arm movement, induration and blue 
spots), six systemic symptoms (fever of 37.7”C or more, 
increased sweating, headache, malaise, insomnia and 
shivering), and the degree of inconvenience these 
symptoms caused (none, slight, moderate or severe). 
Serology 
Prior to intervention, and 1 day and 4 weeks there- 
after, venous blood was taken to determine conventional 
haematological and biochemical parameters and 
serum antibody titres (haemagglutination i hibition test, 
according to standard methods4 with turkey erythro- 
cytes). Sera with undetectable HI-titres (< 10) were 
assigned a titre of five. Serological endpoint variables 
were the geometric mean of post-vaccination HI-titres, 
and the proportion of subjects with post-vaccination 
titres of 40 or more. Results were analysed statistically 
as described previously*, including regression models to 
control confounding factors. A P-value of 0.05 or less 
was considered to indicate statistical significance. 
RESULTS 
Modification of study design 
During the first 10 days of the intake period, 15 out of 
91 participants showed side-effects which were clinically 
classified as “moderate” or “severe”, including nausea 
(sometimes with vomiting) within the first 3 days after 
intervention, high or prolonged fever (239°C several 
days), and polyarthralgia. It was decided by the clinical 
manager outside the study site to unblind the code for 
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these subjects. Seven of 15 cases of moderate or severe 
side-effects were associated with a dose of 50 mg 
GMDP. It was decided and communicated to the 
investigator to withdraw the dose of 50 mg GMDP from 
the ongoing trial. The study was continued with the 
remaining doses of GMDP of 0, 5 and 25 mg, still under 
double-blind conditions. 
Mortality during the study 
In the course of the intake period (1 month) 11 of 120 
nursing home residents who did not take part of the 
study (9.2%), and five of the 153 study participants 
(3.3%) died. This incidence of mortality was within the 
normal range encountered in the home. Four of the 
study participants who died did so with causes unrelated 
to GMDP (cardiac infarction, urosepsis, sudden death). 
In one case, a causal relationship with GMDP could 
neither be excluded nor confirmed. This subject (female, 
75 years of age, history of stroke, aneurysm of the aorta, 
cataract, dementia) was in a weak, but not terminal 
condition, when receiving 50 mg GMDP. She developed 
high fever (up to 39.2”C) 1 day thereafter which lasted 
for 5 days, and a deterioration of her overall condition 
until her death on the seventh day after intervention. 
Autopsy was rejected by her relatives. 
One hundred and forty-eight subjects completed the 
study (Table 1) of which 38 were males and 110 females, 
with an age-range of 41-97 years (mean 80.3). Most of 
the subjects (96.6%) were 60 years or older. 
Side-effects 
The most frequently reported local side-effects were 
redness and warmth at the site of vaccination (23.6% 
and 22.3%, respectively), the most frequently reported 
systemic side-effects were malaise and fever (27.0% 
and 1 l.S%, respectively). Any local and any systemic 
symptom were reported by 37.2% and 29.7% of the 
participants, respectively (Table 2). Females reported 
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Table 3 Seroresponse against three influenza vaccine components 
A-H3N2 A-HlN1 
GMDP(mg) N Pre Post Pre Post 
0 
Pre Post 
(A) Geometric mean titre (95% Cls) 
0 42 12 (9-17) 
5 43 14 (9-21) 
25 40 14 (9-21) 
50 23 16 (9-28) 
All 148 14 (11-17) 
(B) Number of subjects (%) with titre 240 
0 42 8 (19.0) 
5 43 12 (27.9) 
25 t: 10 (25.0) 
50 5 (21.7) 
All 148 35 (23.6) 
40 (27-59) 
28 (17-45) 
52 (32-87) 
55 (32-94) 
41 (32-51) 
24 (57.1) 21 (50.0) 
21 (48.8) 14 (32.6) 
27 (67.5) 18 (45.0) 
15 (65.2) 12 (52.2) 
87 (58.8) 65 (43.9) 
34 (19-61) 
15 (lo-23j 
24 (15-40) 
30 (13-57) 
24 (19-31) 
94 (57-l 53) 
43 (25-71) 
59 (36-97) 
64 (33-126) 
62 (48-81) 
34 (81 .O) 
25 (58.1) 
26 (65.0) 
16 (69.6) 
101 (68.2) 
57 (34-95) 
54 (3S90) 
41 (25-67) 
52 (28-97) 
51 (39-65) 
25 (59.5) 
26 (60.5) 
24 (60.0) 
17 (73.9) 
92 (62.2) 
171 (116-252) 
171 (110-261) 
180 (112-289) 
136 (68-274) 
167 (133-210) 
37 (88.1) 
38 (88.4) 
36 (90.0) 
19 (82.6) 
130 (87.8) 
significantly more local side-effects than males (44.5% vs 
15.8%). Psychogeriatric patients (including those with 
dementia) reported significantly less systemic side- 
effects than somatic patients (15.5% vs 48.4%). Systemic 
symptoms, and moderate or severe inconvenience, but 
not local symptoms, showed a clear dependency on the 
dose of GMDP. Frequencies of side-effects in the 50 mg 
dose arm may have been under-reported as the study 
population, until the withdrawal of the 50 mg dose, 
consisted of less females and more psychogeriatric 
subjects than thereafter (distribution bias). 
Three subjects (50,25 and 25 mg GMDP) complained 
of joint pains lasting several days and completely resolv- 
ing thereafter. Clinically, this symptom appeared as a 
transitory poly-articular arthritis as is seen in serum- 
sickness. Within the first 3 days after intervention, some 
other symptoms occurred whose relationship with inter- 
vention was regarded unclear or unlikely. Three subjects 
(all 0 mg GMDP) developed dizziness, one subject (5 mg 
GMDP) had abdominal pain, one subject (0 mg GMDP) 
showed walking difficulties, one subject (25 mg GMDP) 
had diarrhoea (another patient on the same ward, not 
treated with GMDP, had diarrhoea as well), one subject 
(25 mg GMDP) suffered a stroke and another subject 
(25 mg GMDP) a myocardial infarction. 
Biochemistry and haematology 
GMDP had no meaningful effect on potassium, 
sodium, creatinine, alkaline phosphatase, y-GT and 
total protein. ASAT, total bilirubin and ALAT were 
slightly elevated in the 25, and 50 mg GMDP arms one 
day after intervention, but back to baseline values after 
4 weeks. 
Of the haematological variables, the red blood 
cell parameters (erythrocytes, haematocrit and haemo- 
globin) did not show meaningful changes after 
intervention. Data on thrombocytes were inconclusive. 
White blood cell counts markedly increased after intake 
of GMDP: before intervention, the mean leucocyte 
count in the whole study population was 6.74 x lo9 1-l 
(95% CI: 6.42-7.05). One day after intervention, the 
leucocyte means for the four study arms (0, 5,25 and 50 
mg GMDP) were 6.41, 7.97, 10.55 and 11.73 x lo9 l-‘, 
respectively. The 25 and 50 mg GMDP groups showed 
significantly higher counts of monocytes, and neu- 
trophils, and significantly lower counts of basophils and 
eosinophils, compared to those with placebo or 5 mg 
GMDP. Data on lymphocytes were inconclusive. After 
4 weeks all white blood cell counts had returned to 
baseline-levels. 
HI-antibody prior to and after vaccination 
Table 3 shows the pre- and post-vaccination status 
of the serological variables. Prior to vaccination, and 
4 weeks after vaccination, the variables were similar 
through the four dose groups for any influenza strain 
(PO.05). An effect of GMDP on the serological variables 
could not be detected. Post-vaccination endpoint 
variables were subjected to linear regression, and 
logistic regression, respectively, as described previously’, 
with pre-vaccination titres, age, gender, influenza 
vaccinations within the previous 5 years, influenza-like 
illness during the last winter season, underlying disease 
category, baseline number of lymphocytes and number 
of neutrophils before and 1 day after vaccination, as 
independent variables. Pre-vaccination titres and status 
of previous vaccinations contributed significantly to 
post-vaccination variables. Corrected post-vaccination 
titres were calculated by eliminating the influence of 
pre-vaccination titres and status of previous vaccina- 
tions. These were also similar through the four dose 
groups (not shown). 
DISCUSSION 
Taken together, our data showed that GMDP is 
bio-available after oral administration as it induces a 
mild, clinically irrelevant hepatic activity, and a marked, 
dose-dependent increase of circulating total leucocytes, 
monocytes and neutrophils. This leucocyte-stimulating 
effect of GMDP has been described previously’. 
Furthermore, oral administration of GMDP, in 
combination with inactivated influenza vaccine, causes 
an increase in the frequency of vaccine-associated sys- 
temic side-effects (like fever, headache, malaise), but not 
of local side-effects (like redness or pain of the injection 
site). Moreover, three cases of a mild transitory poly- 
articular arthritis occurred in the 25 mg and 50 mg dose 
arms (4.8%). This dose-dependent increase of side-effects 
was not expected as trials in human beings with GMDP 
alone had not revealed any side-effects attributable to 
GMDP (unpublished data). 
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Finally, sero-response to influenza vaccine in the 
present study population of aged nursing home residents 
was, at least for the influenza A strains: sub-optimal and 
deserved augmentation: Percentages of post-vaccination 
titres 240 were only 58.8% and 68.2% for A-H3N2 and 
A-HlNl, respectively. 
A single oral dose of GMDP did not result in an 
improved sero-response on influenza vaccination in 
elderly nursing home residents. 
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